The deal is the latest to add to Gilead's presence in cancer immunotherapy, an approach to treating cancer that harnesses the body's immune system.
Gilead just made a $4.9 billion bet on cancer-drug maker Forty Seven, whose stock skyrocketed 62%
- Yahoo!
- 2. 3 2020 (15:51)